News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Why Eli Lilly (LLY) Execs are Bullish About Its Alzheimer's Drug Solanezumab 8/23/2016
Struggling Tokai Pharma (TKAI) Nixes Enrollment in Mid-Stage Prostate Cancer Study 8/23/2016
CytoDyn (CYDY) Release: Patients Approach Two Years Of Complete HIV Viral Load Suppression In Phase IIb PRO 140 Monotherapy Extension Study 8/23/2016
ImmunoPhotonics Announces First Patient Dosed In A Randomized, Controlled Breast Cancer Clinical Trial For Incvax – A Novel Investigational Immuno-Oncology Therapy 8/23/2016
Lycera Announces Initiation Of Phase 2 Clinical Trial Of LYC-30937-EC In Patients With Ulcerative Colitis 8/22/2016
BioPharmX Announces Final Phase 2a Trial Results Find BPX-01 Reduces Facial P. Acnes By More Than 90% In Four Weeks 8/22/2016
A Look at Amgen (AMGN)'s Pipeline: Will it Help the Company Grow? 8/19/2016
Xenetic Biosciences Announces FDA Acceptance Of Investigational New Drug Application To Initiate Phase II Clinical Trial Of Virexxa In Endometrial Cancer 8/19/2016
Cerulean (CERU) Shares Decimated as Renal Cell Carcinoma Drug Comes Up Short in Mid-Stage Study 8/18/2016
Aclaris (ACRS) Announces Positive Results In Phase II Clinical Trial Of A-101 For Treatment Of Common Warts 8/18/2016
Cerulean (CERU) Announces Results From Phase 2 Clinical Trial Of CRLX101 And Avastin Combination In Relapsed Renal Cell Carcinoma 8/18/2016
Boston's Juniper Pharma (JNP) Terminates Development of Lidocaine Bioadhesive Gel After Phase II Trial Failure 8/18/2016
ARCA biopharma Announces 100th Patient Randomized Into The GENETIC-AF Phase 2B/3 Clinical Trial 8/18/2016
INSYS Announces First Patient Enrolled In Phase II Trial For The Treatment Of Cocaine Dependence Using Pharmaceutical Cannabidiol 8/18/2016
Nordic Nanovector Completes Recruitment Of The First Cohorts Of Arm 3 And Arm 4 Of Expanded Phase 1/2 Study Of Betalutin In NHL Patients 8/18/2016
Inspyr (GNSZ) Announces The Initiation Of A Phase 2 Clinical Trial Of Mipsagargin For Newly Diagnosed Prostate Cancer Patients 8/17/2016
Oncoceutics Awarded FDA Orphan Grant For ONC201 Multiple Myeloma Trial 8/17/2016
Ark Biosciences Of Shanghai Starts Phase II Trial Of Novel RSV Treatment 8/17/2016
Janssen R&D Release: Esketamine Receives Breakthrough Therapy Designation from FDA for Major Depressive Disorder with Imminent Risk for Suicide 8/16/2016
Three CardioCell-Sponsored Studies Reveal Results At The European Society of Cardiology Congress 2016 8/16/2016
CASI Pharma (CASI) Met Endpoint in Phase II ENMD-2076 in Fibrolamellar Carcinoma 8/16/2016
vTv Therapeutics (VTVT) Completes Enrollment Of Phase 2 Trial Evaluating TTP273 For The Treatment Of Type 2 Diabetes 8/16/2016
Millendo Therapeutics Announces Initiation Of Phase 2b Clinical Trial Of MLE4901 In Patients With Polycystic Ovary Syndrome 8/16/2016
Ascendis Pharma A/S Announces R&D Update To Review Expanded Pipeline And Long-Term Strategic Outlook 8/16/2016
Axovant (AXON) Announces Expansion Of Dementia Pipeline And Reports Financial Results For The First Fiscal Quarter Ended June 30, 2016 8/16/2016
Bristol-Myers Squibb (BMY) Investors: Wait on Opdivo Data to See Potential in Lung Cancer 8/15/2016
Aurinia (ISA.TO)'s Voclosporin Meets Primary Endpoint in Phase IIB Aura-LV Study in Lupus Nephritis 8/15/2016
ProNAi Therapeutics Shuts Down Research Site for Failed Cancer Candidate PNT2258 8/15/2016
NovaDigm Therapeutics Announces Positive Results From First-Ever Antifungal Immunotherapy In A Phase 2a Study In Women With Recurrent Vulvovaginal Candidiasis (RVVC) 8/15/2016
AVEO Oncology (AVEO) Initiates The Evaluation Of Tivozanib In Combination With Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) In Advanced Renal Cell Carcinoma 8/15/2016
MMJ PhytoTech Ltd To Commence Phase 2 Clinical Trial On Pediatric Epilepsy 8/15/2016
Neurotrope Submits An Amended Protocol To The FDA For Its Phase 2b Clinical Trial Of Its Lead Drug Candidate, Bryostatin-1, For The Treatment Of Advanced Alzheimer's Disease 8/15/2016
Tonix Pharma (TNXP) Presents Poster On The Development Of TNX-102 SL For Post-Traumatic Stress Disorder (PTSD) At The 2016 Military Health System Research Symposium 8/15/2016
ProMetic Life Sci (PFSCF.PK) Completes Patients' Enrolment In Pivotal Plasminogen Phase 2/3 Clinical Trial 8/11/2016
Advaxis (ADXS) Announces That Phase II Head And Neck Cancer Study With AXAL Advances To Second Stage 8/11/2016
CryoPort Expands Agreement With Stemedica Cell Technologies, Inc. To Support A Phase II Clinical Trial To Assess A Stem Cell Therapy For The Treatment Of Alzheimer's Disease 8/11/2016
Achillion (ACHN) Announces Upcoming Presentation Of Interim Phase IIa Results From The Janssen Pharmaceutical Sponsored Trial Of Odalasvir, AL-335 And Simeprevir At The European Association For The Study Of The Liver (EASL) Special Conference 8/11/2016
Medivir (MVRBF): New Interim Phase IIa Data On Simeprevir In Combination With Other Daas Will Be Presented At The Upcoming EASL AASLD Special Conference 8/11/2016
12-Employee Lexington Biotech, Aldeyra (ALDX) Shows Off Positive Drug Trial Data 8/10/2016
Oncolytics Biotech Inc. (ONC.TO) Reports Additional Data From Randomized Phase II Study Of REOLYSIN In Non-Small Cell Lung Cancer 8/10/2016
vTv Therapeutics (VTVT)' TTP399 Met Primary Endpoint in Phase IIb Study for Type 2 Diabetics 8/10/2016
Viamet Release: Positive Interim Clinical Results For VT-1161 To Be Presented At The Infectious Diseases Society For Obstetrics And Gynecology Annual Meeting 8/10/2016
Ablynx (ABLYF) Reports Compelling Topline Phase Ilb Study Results With Its Anti-Il-6r Nanobody, Vobarilizumab, In RA Patients, Confirming Its Best-In-Class Potential 8/9/2016
Windtree Therapeutics (WINT) Receives $2.6 Million SBIR Grant To Support AEROSURF Phase 2b Clinical Trial 8/9/2016
Can-Fite BioPharma (CFBI)'s Phase II/III Psoriasis Study Results Published In Journal Of Drugs In Dermatology 8/8/2016
San Diego’s Pfenex (PFNX) Regains Full Rights to PF582 and Announces Phase I/II Results 8/8/2016
Antibe Therapeutics (ATE.V) Announces Successful Phase 2 Trial Of ATB-346 In Osteoarthritis 8/8/2016
BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA For Pancreatic Cancer 8/8/2016
Ionis Pharma (IONS) Investors Still Nervous Despite Upbeat Trial Data Presented Earlier This Week 8/5/2016
Bellicum (BLCM) Announces BPX-501 European Regulatory Updates 8/5/2016
Esperion (ESPR) Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results 8/5/2016
Momenta (MNTA) Halts Enrollment in Necuparanib Phase II Per Recommendation From the Independent Data Safety Monitoring Board 8/4/2016
BioDelivery (BDSI) Announces Randomization Target Reached In Clinical Trial Of Clonidine Topical Gel For The Treatment Of Painful Diabetic Neuropathy 8/4/2016
DNAtrix, Inc. Awarded FDA Orphan Products Development Grant For DNX-2401 8/4/2016
Lexicon Pharma (LXRX) Provides Clinical Pipeline Update And Reports 2016 Second Quarter Financial Results 8/4/2016
HedgePath Pharmaceuticals Announces Positive Interim Data In Its Phase II(B) Cancer Trial 8/3/2016
MorphoSys AG Successfully Completes Safety Run-in Of MOR208 In L-MIND Combination Study In Patients With DLBCL 8/3/2016
Synthetic Biologics (SYN) Announces Completion Of End Of Phase 2 Meeting With FDA For SYN-010, Intended For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C) 8/2/2016
VM BioPharma Announces Korea Food And Drug Administration Approval Of Phase 2 Clinical Trial For Investigational Gene Therapy VM202 In Ischemic Heart Disease 8/2/2016
TheraVasc Achieves Major Milestone In Development Of Non-Addicting And Non-Sedating Pain Medication To Treat Diabetic Neuropathy 8/2/2016
MEI Pharma (MSHL)'s Pracinostat Called a Breakthrough By the FDA 8/1/2016
SCYNEXIS, Inc. (SCYX) Announces Interim Results From Phase II Study Of Oral SCY-078 In Patients With Invasive Candidiasis 8/1/2016
Heron (HRTX) Reports Positive Top-Line Results from Phase 2 Studies Of HTX-011 For Management Of Post-Operative Pain 8/1/2016
Mast Therapeutics (MSTX) Announces Initiation Of Phase 2 Study Of AIR001 Conducted By The Heart Failure Clinical Research Network 8/1/2016
Vaccinex, Inc. Receives FDA Fast Track Designation For VX15 Antibody For The Treatment Of Huntington’s Disease 8/1/2016
Zynerba (ZYNE) Announces Dosing Of First Patients In Phase II STAR 1 Clinical Study Of ZYN002 CBD Gel In Adult Epilepsy Patients With Refractory Focal Seizures 8/1/2016
RedHill Biopharma (RDHL) Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis 8/1/2016
Zynerba (ZYNE) Announces Dosing Of First Patients In Phase II STAR 1 Clinical Study Of ZYN002 CBD Gel In Adult Epilepsy Patients With Refractory Focal Seizures 8/1/2016
SciFluor Life Sciences, LLC Enters Clinical Trial Stage For Novel Treatment For Retinal Diseases 8/1/2016
Angle: Use Of Parsortix In GANNET53 Drug Trial 8/1/2016
Asterias Biotherapeutics To Report Second Quarter Results On August 15, 2016 8/1/2016
Provectus Announces Poster Presentation On PV-10 For Melanoma At European Society For Medical Oncology 2016 Congress 8/1/2016
Seres Therapeutics (MCRB) Craters in Phase II ECOSPOR Study; CEO and Execs Profit on Insider Sales 7/29/2016
Neurocrine Biosciences (NBIX) Announces Initiation Of A Long-Term Phase II Clinical Study Of VMAT2 Inhibitor Valbenazine In Tourette Syndrome 7/29/2016
Shire (SHPG)'s SHP626 Granted FDA Fast Track Designation As Investigational Treatment In NASH With Liver Fibrosis 7/29/2016
Biophytis Receives Approval Of Bpifrance For An Innovation Loan Of €1.1 Million To Finance The SARA-PK Trial 7/29/2016
Quark Pharmaceuticals Inc. Awarded Key Patent For QPI-1007 Ocular Neuroprotectant 7/29/2016
Eli Lilly (LLY) Release: New Studies Suggest Relationship Between Tau Pathology And Progression Of Alzheimer's Disease 7/28/2016
Oramed (ORMP) Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering Of Glucose Levels Vs Placebo 7/28/2016
Anavex (AVXL) Plummeted on Phase IIa Alzheimer's Results "Considered" Positive 7/28/2016
Chase Pharma Presents Phase 2 Results For CPC-201 At 2016 Alzheimer’s Association International Conference 7/28/2016
Chugai Pharma's Emicizumab Showed Continued Benefits In Patients With Hemophilia A 7/28/2016
vTv Therapeutics Announces Presentation Of Phase 2b Azeliragon Results At The 2016 Alzheimer’s Association International Conference (AAIC) 7/28/2016
Millendo Therapeutics Announces Publication Of Positive Phase 2a Data For MLE4901 For The Treatment Of Polycystic Ovary Syndrome 7/28/2016
Caladrius Biosciences (CLBS) Receives FDA Fast Track Designation For CLBS03 To Treat Recent Onset Type 1 Diabetes 7/28/2016
Agenus (AGEN) Reports Second Quarter 2016 Financial Results And Operational Progress 7/28/2016
Nektar Therapeutics (NKTR) To Announce Financial Results For The Second Quarter 2016 On Wednesday, August 3, 2016, After Close Of U.S.-Based Financial Markets 7/28/2016
Karyopharm (KPTI) To Present Updated Phase II Clinical Data From SIGN Study At European Society Of Medical Oncology 2016 Annual Meeting 7/28/2016
Neurovance Announces Positive Centanafadine Phase 2b Results For Adult ADHD, And Plans For Phase 3 Trials 7/27/2016
Gamida Cell Announces First Patient With Sickle Cell Disease Transplanted In Phase 1/2 Study Of Cordin As The Sole Graft Source 7/27/2016
LSK BioPharma Announces Successful Outcome From End-Of-Phase 2 Meeting With FDA 7/26/2016
Poxel Announces Publication Of Important New Mechanism Data For Imeglimin Relating To Insulin Secretion In The Treatment Of Type 2 Diabetes 7/26/2016
Parion Sciences Announces Initiation Of Phase II Clinical Trial Of P-321 For The Treatment Of Dry Eye Disease 7/26/2016
BrightFocus Foundation Release: Health-Ebrain Study To Launch Phase II 7/26/2016
Flex Pharma (FLKS) Completes Enrollment Of Human Proof-Of Concept Efficacy Study In Nocturnal Leg Cramps 7/26/2016
Eisai Inc. (ESALF.PK) And Halozyme (HALO) Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20 7/26/2016
Janssen Biotech (JNJ) Announces Clinical Collaboration With Bristol-Myers Squibb (BMY) To Evaluate Immuno-Oncology Combination In Lung Cancer 7/26/2016
BioInvent (BOVNF) Interim Report 1 January – 30 June 2016 7/26/2016
Synthetic Biologics (SYN) To Report Second Quarter 2016 Operational Highlights And Financial Results On August 3, 2016 7/26/2016
Gradalis Inc. Appoints Martin J. Birkhofer, M.D. Chief Medical Officer 7/26/2016
Tobira (TBRA) Stock Loses More Than Half Its Value After Phase IIb Trial Miss 7/25/2016
Vtesse Bags Another $17 Million to Support Further Product Development and Expand Ongoing Clinical Trials 7/25/2016
Merck & Co. (MRK) Nabs Breakthrough Tag for Ebola Zaire Vaccine From the FDA and PRIME Status From EMA 7/25/2016
Can-Fite BioPharma (CFBI) Completes Phase II Study Design For CF102 In The Treatment Of NASH/NAFLD 7/25/2016
Eiger Biopharma Announces First Patient Dosed In Phase 2 ULTRA Study Of Ubenimex In Secondary Lymphedema 7/25/2016
PTC Therapeutics (PTCT) Provides Regulatory Update On Translarna (Ataluren) 7/25/2016
Tobira (TBRA) To Host Conference Call At 8:30 A.M. Eastern Time Tomorrow To Discuss CENTAUR Phase 2b Trial Results 7/25/2016
Why Investors Should Pay Attention to Seattle Genetics (SGEN)' Drug Trial 7/22/2016
ViaCyte Awarded New CIRM Grant To Develop PEC-Direct For High-Risk Type 1 Diabetes 7/22/2016
Diversity Of Eli Lilly (LLY)'s Alzheimer's Disease Pipeline Showcased At The Alzheimer's Association International Conference 2016 (AAIC 2016) 7/21/2016
DNAtrix, Inc. Announces Successful Intratumoral Delivery Of DNX-2401 Via Alcyone's MEMS Cannula For The Targeted Treatment Of Recurrent Glioblastoma 7/21/2016
Advaxis (ADXS)’ AXAL Receives Fast Track Designation By The FDA As Adjuvant Therapy For High-Risk Locally Advanced Cervical Cancer Patients 7/21/2016
Rhythm Announces The New England Journal of Medicine Publication Of Setmelanotide Phase 2 Data For Treatment Of POMC Deficiency Obesity 7/21/2016
Novan Announces First Patient Dosed In Phase 2 Anti-Fungal Program 7/21/2016
CytoDyn (CYDY) Submits Orphan Drug Application To FDA For Pretreatment With PRO 140 Of Treatment-Naïve HIV Patients 7/21/2016
BioPharmX Study Shows BPX-01 Topical Gel Delivers Minocycline Precisely To The Skin 7/21/2016
Hansa Medical Interim Report April – June 2016 7/21/2016
Eiger Biopharma Announces Completion Of Dosing In Phase 2 LOWR HDV - 3 Study At NIH 7/20/2016
Cell Medica Release: Lead Cancer Immunotherapy Candidate Granted EU Orphan Drug Designations 7/20/2016
CytoDyn (CYDY) Submits Protocol for Phase IIb Trial for Treatment Naïve HIV Patients 7/19/2016
Cerulean Pharma Inc. (CERU) Receives FDA Fast Track Designation For CRLX101 For The Treatment Of Platinum-Resistant Ovarian Cancer 7/19/2016
Hansa Medical Initiates Pivotal Multicenter Study In The U.S. With Ides For Treatment Of Refractory Highly Sensitized Kidney Patients 7/19/2016
Antibe Therapeutics (ATE.V) Announces the Appointment of New Board Member and Provides Update on Phase 2 Trial of ATB-346 7/19/2016
Juno (JUNO) Stock Falls Again After Correcting Number of Trial Deaths 7/18/2016
Soligenix (SNGX) Announces Presentation Of Positive Preliminary Results Of A Heat Stable Ebola Vaccine Formulation 7/18/2016
BrainStorm Cell Announces Positive Top Line Results From The U.S. Phase 2 Study Of NurOwn In Patients With Amyotrophic Lateral Sclerosis (ALS) 7/18/2016
Seattle Genetics (SGEN) And Takeda (TKPYY) Announce Publication Of Final Data From ADCETRIS (Brentuximab Vedotin) Monotherapy Pivotal Phase II Clinical Trial In Relapsed Or Refractory Classical Hodgkin Lymphoma In Blood 7/18/2016
Eiger Biopharma Announces First Patient Dosed In Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension 7/18/2016
HYD Receives Ethical Approval For Phase 2 Clinical Trial Investigating The Anticancer Effect Of Deuterium Depletion In CLL 7/18/2016
Armagen Presents Data From First Cohort Of Phase 1/2a Of AGT-182 For Treatment Of Hunter Syndrome 7/15/2016
Panther Biotechnology Announces The Initiation Of Formal Development Of Transferrin Doxorubicin Conjugate 7/15/2016
BrainStorm Cell To Announce Top Line Results From The U.S. Phase 2 Study of NurOwn In Patients With Amyotrophic Lateral Sclerosis (ALS) On Monday, July 18 7/15/2016
SAGE Therapeutics (SAGE)' Stock Explodes as Drug Eliminates Postpartum Depression in Mid-Stage Study 7/14/2016
Juno (JUNO) Soars After the FDA OKs Restart of Clinical Trial 7/14/2016
vTv Therapeutics Announces Phase IIb Azeliragon Data Selected For Oral Presentation At The 2016 Alzheimer’s Association International Conference 7/14/2016
Enteris Biopharma Initiates Clinical Program For Tobrate (Oral Tobramycin Tablet) In Uncomplicated Urinary Tract Infection 7/13/2016
Akari Therapeutics Receives Approval From The UK Medicines & Healthcare Products Regulatory Agency To Conduct Phase II Trial In Paroxysmal Nocturnal Hemoglobinuria 7/13/2016
Agile Therapeutics, Inc. Announces Plans To Advance Contraceptive Pipeline 7/13/2016
Inotek Pharmaceuticals Corporation (ITEK) Initiates Phase 2 Dose-ranging Trial Of A Fixed-Dose Combination Of Trabodenoson, A Novel Treatment For Glaucoma, And Latanoprost 7/13/2016
3 Nauseating Clinical Trial Flops of 2016 So Far 7/12/2016
Aviragen Resumes Enrollment In Phase IIa RSV Challenge Trial 7/12/2016
Asterias Biotherapeutics Completes Enrollment And Dosing For The First Efficacy Cohort Of The AST-OPC1 Scistar Phase 1/2a Clinical Trial In Complete Cervical Spinal Cord Injury 7/12/2016
Synthetic Biologics (SYN) Announces Granting Of European And U.S. Composition Of Matter Patents For Ribaxamase 7/12/2016
Juno (JUNO) Halts CAR-T Cancer Trial After Three Patient Deaths 7/11/2016
In Juno (JUNO) Patient Deaths, Echoes Seen Of Earlier Failed Company Dendreon (DNDN) 7/11/2016
Sucampo (SCMP) Terminates Development of Cobiprostone Following Phase II Data 7/11/2016
AbbVie (ABBV) Receives U.S. FDA Rare Pediatric Disease Designation For Investigational ABT-414 For The Treatment Of A Type Of Pediatric Brain Tumor Known As Diffuse Intrinsic Pontine Glioma (DIPG) 7/11/2016
NLS Pharma Group Release: Mazindol Granted Orphan Drug Designation In The US & Europe For Treatment Of Narcolepsy 7/11/2016
AbbVie (ABBV)'s $175 Million Gamble Pays Off as Ablynx (ABLYF) RA Drug Meets Goal in Phase II Study 7/8/2016
Pfizer (PFE) Stock Climbs With Positive Renal Cancer Phase III Data 7/8/2016
Alnylam (ALNY) Initiates Phase 1/2 Clinical Trial For ALN-HBV, An Investigational RNAi Therapeutic For The Treatment Of Chronic Hepatitis B Virus Infection 7/8/2016
Kite Pharma (KITE) Completes Enrollment Of All Patients With Diffuse Large B-Cell Lymphoma (DLBCL) In Pivotal Multi-Center Phase 2 Study Of KTE-C19 (ZUMA-1) 7/8/2016
Ionis Pharma (IONS) Reports Positive Clinical Data On IONIS-TTR Rx At The XV International Symposium On Amyloidosis 7/7/2016
Puma Biotech (PBYI) Announces I-SPY 2 Phase II Study Of Neratinib Published In The New England Journal of Medicine 7/7/2016
ColonaryConcepts Successfully Completes Phase II Study For A New Approach To Colonoscopy Prep For Colorectal Cancer Screening 7/7/2016
Juniper Pharma (JNP) Announces Completion Of Enrollment In Phase 2b Clinical Trial Of COL-1077 10% Lidocaine Vaginal Gel For Gynecologic Procedure Pain 7/7/2016
Synthetic Biologics (SYN) Receives USAN Approval For Generic Name Ribaxamase For Phase 2 Drug Candidate SYN-004 7/7/2016
Catabasis (CATB) Announces The Initiation Of An Open-Label Extension For The Movedmd Trial Studying Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy 7/7/2016
This Year’s Top 10 Disappointing Clinical Trials—So Far! 7/6/2016
Sanofi Genzyme (SNY) Begins Pivotal Phase II/III Trial Of Olipudase Alfa For Adult Patients With Acid Sphingomyelinase Deficiency 7/6/2016
FDA Grants Merrimack (MACK) Fast Track Designation For Seribantumab (MM-121) In Non-Small Cell Lung Cancer 7/6/2016
RiboMed Biotechnologies, Inc. And Tocagen Inc. Collaborate To Analyze Epigenetic Prognostic Markers, Including MGMT, In Recurrent Brain Tumors 7/6/2016
OphthaliX Inc. Announces Phase II Glaucoma Data 7/5/2016
NeuroDerm (NDRM) Announces Start Of U.S. Patient Enrollment In Trial 006, A Phase II Trial Of ND0612H For Advanced Parkinson’s Disease 7/1/2016
Shire (SHPG)'s Retinopathy Treatment Fails to Meet Primary Endpoint in Phase II 7/1/2016
Infinity Pharma (INFI) Cuts Jobs by 58% as AbbVie (ABBV) Terminates Duvelisib Collaboration Deal 6/30/2016
Novartis AG (NVS) PKC412 (Midostaurin) Pivotal Data Published In The New England Journal of Medicine Show 60% Response Rate In Advanced Systemic Mastocytosis (SM) 6/30/2016
Global Blood Therapeutics (GBT) Announces Initiation Of Phase 2a Study Of GBT440 In Adolescents With Sickle Cell Disease 6/30/2016
Poxel SAS Announces Patient Enrollment Completed For Imeglimin Phase 2b Clinical Trial In Type 2 Diabetes In Japan 6/30/2016
Zytoprotec GmbH Completes Enrollment In Phase II Study With Novel Peritoneal Dialysis Fluid 6/30/2016
BioMarker Strategies Awarded Phase I/II Fast Track National Cancer Institute Grant To Develop Companion Diagnostic Test To Select Optimal Therapy For Patients With Non-Small Cell Lung Cancer 6/30/2016
AbbVie (ABBV) Nabs Breakthrough Tag for Ibrutinib to Treat Chronic Graft-Versus-Host-Disease 6/29/2016
BioPharmX Announces Positive Topline Phase 2a Clinical Trial Results For BPX-01 In Patients With Acne-Causing Bacteria 6/29/2016
Aurinia (ISA.TO) Announces 24 Week Remission Rates From The First Seven Patients In Its Open Label AURION Study In Lupus Nephritis (LN) 6/29/2016
New Kid Vidac Pharma Completes $9 Million Series A Financing; Advances Phase II VDA-1102 6/29/2016
Oncolytics Biotech Inc. (ONC.TO) Announces Phase 2 Study In Female Patients With Colorectal Cancer Metastatic To The Liver 6/29/2016
Janssen Pharmaceutical Companies Release: Ibrutinib (IMBRUVICA) Granted Breakthrough Therapy Designation By FDA For The Development Of A Treatment For Chronic Graft-Versus-Host Disease (cGVHD) 6/29/2016
NeuroDerm (NDRM) Announces ND0612H Achieves Comparable Pharmacokinetics To DUODOPA In Head-To-Head Pilot PK Comparison Trial 6/29/2016
Marinus Pharma (MRNS)'s Primary Endpoint Not Met in Ganaxolone Phase II 6/28/2016
Zynerba (ZYNE) Announces Positive Top Line Results From ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial And Initiation Of Phase 2 Study In Adult Epilepsy Patients With Refractory Focal Seizures 6/28/2016
Bristol-Myers Squibb (BMY)'s Miracle Drug Opdivo Receives Yet Another Breakthrough Designation 6/28/2016
Immune Pharma Release: New Data Suggests Improved Tumor Response For The Combination of AZIXA and Immune Checkpoint Inhibitors in The Treatment of Cancer 6/28/2016
Mologen (MOLGF.PK): First Patients Enrolled In Extension Phase Of The HIV Study TEACH 6/28/2016
BioLineRx Announces Regulatory Submissions For Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA (Pembrolizumab) For Treatment Of Pancreatic Cancer 6/28/2016
GlycoMimetics, Inc. (GLYC) Doses First Patient In Phase 2 Portion Of Clinical Trial Of GMI-1271 In Newly Diagnosed Acute Myeloid Leukemia 6/28/2016
Ablynx (ABLYF) To Exercise Option To License Vectura (VEC.L)’s FOX Device For Use In Its Forthcoming Phase IIb Efficacy Study Of Its Inhaled Anti-RSV Nanobody (ALX-0171) 6/28/2016
Intensity Therapeutics, Inc. Raises $10 Million To Fund Clinical Supplies Manufacturing And Phase I/II Trials Of INT230-6 6/28/2016
Xencor Provides Updates On Lead Programs And Reviews Bispecific Oncology Partnership; Announces Expansion Of Bispecific Oncology Pipeline At Analyst Day 6/28/2016
Allergy Therapeutics Phase II Fails to Find Hay Fever Therapy Dose Range 6/27/2016
Akcea Therapeutics Announces Publication Of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides And Improved Insulin Sensitivity In Patients With High Triglycerides And Type 2 Diabetes 6/27/2016
Santalis Announces Positive Results From A Study Using 10% East Indian Sandalwood Oil (EISO) Serum Formulation For The Treatment Of Mild-To-Moderate Plaque Psoriasis 6/27/2016
TWi Biotechnology Announces Last Patient Enrolled In Phase 2 Study Of AC-201CR For Gout Treatment 6/27/2016
Stealth Biotherapeutics Initiates Two Phase 2 Trials Evaluating Elamipretide For The Treatment Of Heart Failure 6/27/2016
Alnylam (ALNY) To Report New Patisiran And Revusiran Results At The XV International Symposium On Amyloidosis 6/27/2016
Neurotrope Announces That A New Study Published In The Journal of Biological Chemistry Shows That Bryostatin, A PKC Epsilon Activator, Generates New Synapses Through Accumulation Of The Synaptic Anchoring Protein PSD-95 At Neuronal Membranes 6/23/2016
Reata Pharmaceuticals, Inc. Announces Interim Data From Extension Phase II LARIAT Study In Pulmonary Arterial Hypertension 6/23/2016
Wilson Therapeutics Presents Preliminary Clinical Data On Decuprate At The 20th International Congress Of Parkinson's Disease And Movement Disorders 6/23/2016
BioCon (BIOCON.NS), Quark Pharmaceuticals Inc. Announce Initiation Of Pivotal Phase II/III Study Of QPI-1007 In Rare Eye Disease In India 6/23/2016
Cerulean Pharma Inc. (CERU) Announces First Patient Dosed In Phase 2a Expansion Stage Evaluating CRLX301 In Patients With Advanced Solid Tumors 6/23/2016
Taiwan Liposome Company Completes Trial Enrollment For Arthritis Treatment 6/23/2016



//-->